EMAIL THIS PAGE TO A FRIEND

Journal of biomedical materials research. Part B, Applied biomaterials

Heparin surfaces: Impact of immobilization chemistry on hemocompatibility and protein adsorption.


PMID 24711209

Abstract

Immobilization of heparin to surfaces has been used for decades to reduce the thrombogenicity of blood contacting devices. This study evaluates how the mode of covalent heparin bonding affects the hemocompatibility and uptake of antithrombin on surfaces in whole blood. End-point attached (EPA) heparin, using the proprietary Carmeda Bioactive Surface (CBAS Surface), was compared with other methods of covalent heparin bonding that typically yield multiple covalent linkages (using reductive amination of periodate oxidized native heparin or EDC coupling of native heparin). All heparin surfaces were immobilized on flexible polyvinyl chloride tubing and exposed to fresh non-anticoagulated blood in an in vitro recirculating Chandler loop blood model. After exposure, biomarkers for coagulation and platelet activation were analyzed in the solution phase, and adsorbed plasma proteins were eluted from the heparin surfaces and measured for surface concentration of antithrombin and total adsorbed protein. Only the EPA-heparin surface conferred thromboresistance, as observed by the absence of clotting. Attachment and activation of platelets as well as activation of the clotting cascade was significantly lower on the EPA-heparin surface when compared with the other heparin surfaces. In addition, antithrombin constituted ∼40% of the total adsorbed plasma protein concentration on the EPA-heparin surfaces.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

HPA001198
Anti-BTK antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA002028
Anti-BTK antibody produced in rabbit, Ab2, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB3500372
Anti-BTK antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB4502936
Anti-BTK antibody produced in rabbit, affinity isolated antibody
SAB1400106
Anti-GATM antibody produced in mouse, IgG fraction of antiserum, buffered aqueous solution
SAB2701647
Anti-gatm antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA026077
Anti-GATM antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2103200
Anti-GATM antibody produced in rabbit, affinity isolated antibody
SAB1406820
Anti-TMPRSS11D antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
AV46418
Anti-TMPRSS11D antibody produced in rabbit, IgG fraction of antiserum
SAB2102485
Anti-TMPRSS11D antibody produced in rabbit, affinity isolated antibody
HPA052834
Anti-TMPRSS11D antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB5300137
Monoclonal Anti-BTK antibody produced in mouse, clone 7F12H4, ascites fluid
SAB1402784
Monoclonal Anti-GATM, (N-terminal) antibody produced in mouse, clone 2H7, ascites fluid